| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cost of Revenue | $507K | — | — |
| R&D Expense | $182K | — | +7.3% |
| SG&A Expense | $703K | — | +89.2% |
| Operating Income | -$887K | — | -63.4% |
| Interest Expense | $38K | — | — |
| Net Income | -$923K | — | -71.1% |
| EPS (Basic) | -$0.20 | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12K | -95.0% | — |
| Current Assets | $51K | -83.4% | — |
| Total Assets | $196K | -59.2% | — |
| Current Liabilities | $3.0M | +25.9% | — |
| Total Liabilities | $3.0M | +24.2% | — |
| Stockholders' Equity | -$2.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$350K | — | +13.5% |
| Financing Cash Flow | $125K | — | -37.5% |
| EPS (Diluted) | -$0.20 | — | -33.3% |
| -44.6% |
| -3627.6% |